Wedbush Reaffirms Outperform Rating for Vor Biopharma (NYSE:VOR)

Vor Biopharma (NYSE:VOR)‘s stock had its “outperform” rating reiterated by Wedbush in a research note issued to investors on Thursday,RTT News reports. They currently have a $7.00 target price on the stock.

Other equities analysts also recently issued reports about the company. JMP Securities restated a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. HC Wainwright restated a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vor Biopharma currently has a consensus rating of “Buy” and a consensus price target of $8.86.

Vor Biopharma Price Performance

VOR stock opened at $0.87 on Thursday. The company has a market cap of $59.75 million, a P/E ratio of -0.53 and a beta of -0.40. Vor Biopharma has a 1 year low of $0.63 and a 1 year high of $2.43. The stock’s fifty day moving average price is $1.22 and its 200-day moving average price is $1.01.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Two Sigma Investments LP lifted its position in Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares in the last quarter. Trustees of Columbia University in the City of New York purchased a new position in shares of Vor Biopharma in the fourth quarter valued at about $102,000. RA Capital Management L.P. lifted its position in shares of Vor Biopharma by 74.3% in the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after acquiring an additional 16,897,159 shares in the last quarter. Northern Trust Corp lifted its position in shares of Vor Biopharma by 39.0% in the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after acquiring an additional 44,252 shares in the last quarter. Finally, Lynx1 Capital Management LP purchased a new position in shares of Vor Biopharma in the fourth quarter valued at about $707,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.